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Since the ﬁrst thoracic endograft was placed in 1994 for
descending thoracic aneurysm disease,1 multicentre trials2e4 and
comparative analyses5 have conﬁrmed reduced early morbidity
and mortality over its open counterpart.6 As such, thoracic endo-
vascular repair [TEVAR] is now an accepted treatment for
descending thoracic aortic aneurysm (DTA) in the elderly and high
risk populations.7,8 These techniques have been successfully
adapted for the treatment of other thoracic aortic conditions such
as dissection9,10 and blunt injury,11,12 bringing a younger cohort of
patients and with it, concerns regarding its long term durability
and efﬁcacy. If we can extrapolate from the infrarenal EVAR
experience, early reductions in morbidity and mortality may be
coupled with an increased need for reinterventions and an
uncertainty in long term prevention of aortic related death.13
Similarly, there is no evidence that TEVAR in descending thoracic
aneurysmal disease is superior to its open counterpart for long
term outcomes.6 This paucity of convincing long term data and the
high need for reintervention has led to recommendations for
lifelong surveillance.7,8
Risks of Surveillance
Endograft surveillance in the trauma population presents a very
different set of considerations, and the type and interval for this
younger group of patients is highly controversial and will not be
included in this manuscript. However, the consequences of lifelong
surveillance deserve consideration in the aneurysm and dissection
cohorts given that TEVAR is no longer restricted to the high risk
surgical patient. With this younger and healthier cohort of patients
comes concern that the accumulated radiation dose of treatment
followed by yearly lifelong CT scans places them at increased risk of
radiation induced cancer.14 In some patients, there are also long
term risks to renal function. Forty (40) percent of patients with
descending thoracic aneurysms treated by TEVAR have pre-existing
renal insufﬁciency (GFR < 60 ml/min), and the procedure itself
precipitates a progressive deterioration in chronic renal* Corresponding author. Tel.: þ1 216 445 1338.
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bated by surveillance where patients with a GFR < 45 ml/min have
a 15% risk of contrast induced nephropathy (CIN) after a single
contrast CT angiogram;16 while CIN is potentially reversible, the
development of the condition itself is associated with a twofold
increased rate of stroke, myocardial infarction, dialysis dependent
renal failure and death.17 The mean cost of surveillance is $1800
higher in TEVAR treated patients than in patients treated by open
repair at 2 years follow-up.18Rationale for Surveillance
To justify the costs/risks associated with TEVAR surveillance, it
will be necessary to show that their beneﬁts outweigh these risks
over time. These beneﬁts may include prevention or treatment of
graft related issues, such as endoleak, collapse, and migration, as
well as aortic issues such as remodelling and aneurysmal degen-
eration of contiguous segments. The rationale would be that
intervention for these issues may reduce the risk of aneurysm
related death.Endoleak
Endoleak represents the most common complication after
TEVAR, occurring in up to 30% of patients;19 unlike in the abdom-
inal aorta, it appears that Type I and III endoleaks predominate. This
is a consistent ﬁnding in a number of multicentre trials and single
centre series (Table 1).2e4,20e23 Type I and III endoleaks represent
treatment failure through persistent aneurysmal sac pressurisation
and require immediate treatment to prevent rupture and possible
mortality.24 Type II endoleaks, in particular those from left
subclavian artery (LSCA) coverage at the proximal seal zone, require
intervention as these have been associated with sac enlargement.22
While the majority of these endoleaks are early (<30 days) and can
be treated within the original admission, up to 21% of patients
experience late endoleaks; at up to 2 years of follow-up, 56% of
these required a secondary intervention.25 While most trials have
relatively limited follow-up, Czerny et al. report a 5.7% type I and III
late endoleak rate in 113 TEVAR treated DTA patients prospectively
followed up for a mean of 54 months, after an initial early endoleak
rate of 12.3%.22 Interestingly, they noted that no patient withn Society for Vascular Surgery.
Table 1
Endoleaks.
Studies Year Patients Pathology Mean F/U
(mths, SD, range)
Grafts used Early Endoleak
(%)
Type, % Late Endoleak
(%)
Type, %
Czerny22 2010 113 Aneurysm 54  38 (5e144) Gore Excludera, Medtronic Talentb,
Gore TAGa, Bolton Relayc, Medtronic
Valiantb, Otherse,f
12.3 I and III, 7.9 11.5 I and III
II, 4.4
Piffaretti21 2009 61 Aneurysm 32.4 (1e96) Medtronic Talent, Gore Excluder,
Cook TX1/TX2d
8.2 I, 6.6 6.5 I, 4.9
II, 1.6 II, 1.6
III, 0 III, 0
Preventza20 2008 249 Mixedg 20  19.4 (1e60) Gore TAG 6.4 I, 5.1 8.8 I, 6.1
II, 1.3 II, 1.9
III, 0.8
Makaroun2 2008 140 Aneurysm 37 (3e66) Gore TAG 8.1 I, 6.1 4.3 I, 2.15
II, 1 II, 2.15
III, 1 III, 0
Fairman4 2008 195 Mixedh 12 Medtronic Talent 25.9 I, 4 12.2 I, 4.9
II, 15.5 II, 4.9
III, 1.7 III, 0
Unknown, 4.6 Unknown, 2.4
Matsumura3 2008 160 Mixedh 12 Cook TX2 4.8 I, 0.8 3.9 I, 0
II, 3.2 II, 1.9
III, 0.8 III, 1
Unknown, 1
Morales23 2008 160 Mixedi 36 (0e78) Cook TX1/TX2 9.4 I, 4.4 7.5 I, 1.9
II, 4.4 II, 4.4
III, 0.6 III, 1.2
Leurs25 2007 213 Aneurysm 18  16.1 (1e60) Medtronic Talent, Cook TX2,
Gore Excluder, Endomed Endoﬁte
NR NR 21.1 I, 10.3
II, 3.3
III, 7.5
a Gore TAG, Excluder (W.L. Gore & Associates, Flagstaff, Arizona, USA).
b Medtronic Talent, Valiant (Medtronic Vascular, Santa Rosa, California, USA).
c Bolton Relay (Bolton Medical, Sunrise, Florida, USA).
d Zenith TX1/TX2 (Cook Inc, Bloomington, Indiana, USA).
e Endomed Endoﬁt (Endomed, Phoenix, Ariz, USA).
f Jotec Evita (Jotec, Hechingen, Germany).
g Mixed: Aneurysms (45%), Dissections (27%), Penetrating Aortic Ulcers (11%), Contained ruptures (5%), pseudoaneurysms (4%), aortic transections (4%), aortobronchial
ﬁstulas (3%), Endoleaks (<1%) Coarctation (<1%).
h Mixed: Aneurysms, Penetrating aortic ulcers (Matsumura et al, 86% and 14%; Fairman et al, not stated).
i Mixed: Aneurysms (82%), Chronic Dissection aneurysms (16%), Other (Fistula, aortic ruptures; 2%).
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the same cause, suggesting that late endoleak development may
not be predicted by the presence of early endoleak. In another
series, 7 of 64 persistent endoleaks at up to 40 months follow up
were associated with rupture, and all resulted in mortality.26 Other
reports of aortic rupture in TEVAR treated patients lost to follow up
have been noted at up to 10 years post-procedure.27 Presence of late
endoleak was the only predictor of decreased survival in a single
centre prospective series,28 emphasising the potential hazards of
undetected and untreated late TEVAR complications.
Migration and Collapse
Further complications of TEVAR, including graft migration29
and graft collapse, are not conﬁned to the early post-operative
period, and are also associated with late aortic morbidity and
mortality.30 Device encroachment on arch vessel ostia have been
ascribed to stent graft migration at up to 2 years after implanta-
tion,31 and graft collapse with proximal endoleak have been
observed at up to 3 yrs after implantation.32 Other rare compli-
cations of TEVAR treatment observed include retrograde type A
dissection, seen at up to 4 months post implantation, and aorto-
oesophageal ﬁstula at up to 49 months, both requiring open
conversion for salvage.33
Aortic Remodelling D Detection of Contiguous Aneurysms
In TEVAR treated dissection, surveillance is also required to
assess aortic remodelling, false lumen thrombosis and progressionof aortic disease in segments of contiguous aorta. Both aortic
remodelling and false lumen thrombosis are predictive factors for
survival after TEVAR treated chronic type B dissection;34
surveillance is essential to monitor these endpoints. Failure to
maintain these endpoints commonly lead to reinterventions,
observed in up to 60% of patients in a systematic review of 17
studies and over 500 patients.35 Mid-term (mean 31 months)
complications of distal aortic aneurysmal change and persistent
false lumen blood ﬂow were reported in 8% of the cohort, with
a further 7% having proximal Type I endoleak and 3% having
delayed aortic rupture. In addition to monitoring the TEVAR
treated segment, surveying the evolution of the untreated
segment susceptible to progressive dilatation is essential; in 79
complicated chronic distal aortic dissection patients treated with
TEVAR, 22% subsequently underwent secondary aortic reinter-
ventions predominantly for enlargement of the untreated aorta
remote to stent-graft repair.36
Progression of disease in TEVAR treated DTAs is less well
described than in dissections. Aneurysmal regression in the
absence of endoleak is well reported, but there is little information
on progression of disease in areas remote from the treated segment.
However, we can expect progression in TEVAR treated aneurysmal
disease if we extrapolate from a series of 30 open surgical repair
DTA/TAAA patients found to have aneurysmal degeneration in
contiguous segments of aorta between 4 and 16 years after initial
surgery.37 In these 30 patients, 12 had aneurysmal degeneration (of
>6 cm diameter) proximal to the previous repair, while 14 were
distal. Reported TEVAR follow up to date is likely too short to allow
observation of this phenomenon.
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The literatureof TEVAR indescendinganeurysmaldisease,22 aortic
dissection36,38 would suggest that late complications are ubiquitous,
regardless of treatment indication and model of device used.
Furthermore, there appears to be no obvious threshold of follow-up
duration after which no further complications occur; life threat-
ening late complications have been reported at up to 10 years post
procedure.27As few large series report followup>5years, evidenceof
durability of the device is unknown apart from the knowledge that
complications beyond 5 years exist, and require intervention to
prevent death. At the current time, with the available evidence, it
seems prudent to continue ongoing surveillance for TEVAR as
a duration after which no further complications occur has not been
identiﬁed, but certainly more long term experience is needed.
Options for Surveillance Modalities
While there is evidence to support the need for lifelong surveil-
lance, there is considerable debate on how this should be achieved,
as the potential beneﬁt of lifelong surveillance of the graft may be
outweighed by thedisadvantage of excessive radiation exposure and
cost. Current generation CT scanning is an ideal imaging modality
because it provides isovoxel images that can bemanipulated in three
planes, and with contrast enhancement in delayed phases, can also
detect leaks that are low ﬂow. However, Zoli et al. estimate that the
projected cumulative radiation exposure with CT over 17 years of
follow-up exceeds 350 mSv, with a lifetime attributable risk of
developing leukaemia and solid cancer of between 2.7 and 12%.14
Despite this, patients with predisposing factors for graft complica-
tions may incur a risk of late endoleak, with its attendant morbidity
and mortality,26 that exceeds the risk of radiation induced malig-
nancy, justifying the prioritisation of surveillance. Such predisposing
factors include birdbeaking at the proximal seal zone,39 compro-
mised proximal seal zone due to length or angulation,28 greater
length of aortic coverage and number of components used,40 larger
diameter at proximal seal zone, and coverage of LSCA without
endovascular or open ligation.21 Grafts placed along the lesser curve
of a large aneurysm have the potential for outward migration with
resultant dislocation and type III endoleak.41 In patients whose
grafts have these characteristics, annual surveillance with the
imaging modality that best demonstrates graft failure, regardless of
accumulated radiation dose, should be prioritised.
Consideration of Age
In the younger patient cohorts most at risk of prolonged radi-
ation exposure, more consideration into selection of surveillance
modality is needed in order to minimise radiation load without
compromising surveillance. In groups such as the connective tissue
disease patient, the aortic dissection cohort, and younger
descending thoracic aortic aneurysm patients, follow up is likely to
exceed the 10 year latency period for malignant transformation
following radiation exposure.42 One strategy to reduce exposure
may be to combine a CTA chest with an abdominal and peripheral
ultrasound in patients where the primary clinical interest is the
aneurysmal progression of untreated aortoiliac and femoral
regions, rather than a total body CTA. Where a nitinol based
endograft is used, MRA should be used preferentially to reduce
radiation load; some have argued that they preferentially use
a nitinol based stent graft over a stainless steel counterpart in
patients with a long expected follow-up for this speciﬁc reason.14
Where cost and institutional restrictions limit annual access to
MRI, alternating annual follow-up between CTA and MRA can
prolong the duration of “radiation safe” follow-up, effectivelydoubling the time needed to reach threshold radiation exposure. In
some situations, such as assessing false lumen thrombosis in aortic
dissection, specialised MRI may actually be preferred over CTA due
to its increased sensitivity in detecting the presence of low velocity
ﬂow.43 From a renal safety perspective, although the less nephro-
toxic gadolinium based contrast with MRA may be preferred over
iodinated CT contrast in moderate renal insufﬁciency, caution still
exists in patients with GFR < 30 ml/min where the risks of neph-
rogenic systemic ﬁbrosis remain a concern.44 In any patient with
impaired renal function, the recommended guidelines for renal
protection should be followed.16 Thus, patients with a projected life
expectancy of greater than 10 years and/or renal failure need
greater consideration into surveillance modality selection to
minimise and manage its potential negative impact.
This need for individualised surveillance strategy begs the larger
question of whether endovascular options are truly beneﬁcial over
open options overall, especially in cases where one cannot achieve
both optimal graft surveillance AND radiation and renal safety.
Although some groups use this dilemma to guide optimal choice of
graft, should it rather address the broader question of what the
optimal modality of treatment should be, given the predominant
beneﬁts of endovascular treatment are short term, while the
beneﬁts one seeks to achieve in these younger ﬁtter patients
include the long term?
Conclusion
Finally, it is important to note that endovascular stent grafting is
by its very nature palliative rather than curative in intent, relying on
simply relining the pathological aorta rather than excising and
replacing it by open surgery. The corollary to this is that lifelong
surveillance is essential to monitor the equally lifelong potential for
the endograft to fail. While good outcomes have been achieved in
the elderly and high risk population, the role of endografts in the
younger population has yet to be established, and lifelong
surveillance is critical for determining their true place in the
vascular surgeons’ armamentarium.
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